Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Average Price Target from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given an average recommendation of “Hold” by the five ratings firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $9.33.

ESPR has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Monday, March 25th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. Finally, Bank of America downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 3rd.

Esperion Therapeutics Trading Up 1.9 %

ESPR opened at $2.13 on Friday. The company’s 50 day moving average is $2.43 and its 200-day moving average is $1.98. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a market cap of $403.42 million, a P/E ratio of -1.00 and a beta of 0.84.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the previous year, the business posted ($0.76) earnings per share. On average, equities analysts forecast that Esperion Therapeutics will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ESPR. Simplicity Wealth LLC acquired a new stake in Esperion Therapeutics during the first quarter worth approximately $44,000. Herbst Group LLC acquired a new stake in shares of Esperion Therapeutics during the 1st quarter worth approximately $28,000. Wasatch Advisors LP increased its stake in shares of Esperion Therapeutics by 2.7% in the 1st quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock valued at $24,467,000 after acquiring an additional 238,544 shares in the last quarter. Capital Advisors Wealth Management LLC acquired a new position in shares of Esperion Therapeutics during the 1st quarter valued at $58,000. Finally, GSA Capital Partners LLP boosted its stake in Esperion Therapeutics by 1.0% during the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock worth $3,373,000 after acquiring an additional 11,494 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.